Xlife Sciences AG (XLS): Antiviral drug candidate
17.2.2021 10:44:00 EET | Business Wire | Press release
A portfolio project of Xlife Sciences AG (XLS) is developing a promising drug candidate against SARS-CoV-2 as well as other flu viruses. The active ingredient inhibits the viral replication and acts against infection related inflammatory processes. It is already in use in humans.
Research & Development is actively looking for Covid-19 therapies around the world. In this way, the aim is to focus on reducing viral replication in early stages and to treat inflammatory effects at a later stage.
The drug candidate developed by the portfolio project company of Xlife Sciences AG has shown that it can offer an alternative therapeutic approach in several phases of the disease, as it both reduces the viral load and inhibits inflammation in the body.
Oliver R. Baumann, CEO of Xlife is delighted about the latest results: "We are very confident that the medical drug can be used in various phases of Covid-19 due to its specific properties and are pleased to contribute to fighting the global pandemic". Baumann added that it can be assumed that the active principle can be transferred to other respiratory viruses as well. This is subject to further research.
According to Xlife, the drug candidate has efficiently reduced the viral load of lung cells infected with influenza in several cell experiments. Tests with SARS-CoV-2 pathogens have also shown a high level of effectiveness. In addition, various inflammatory processes in the body have been effectively combated. The active ingredient is already being used in humans.
About Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch
|
Language: |
English |
|
Company: |
Xlife Sciences AG Klausstrasse 19 8008 Zürich Switzerland |
|
Phone: |
0041 44 385 84 60 |
|
E-mail: |
|
|
Internet: |
|
|
ISIN: |
CH0461929603 |
|
WKN: |
A2PK6Z |
|
Listed: |
Regulated Unofficial Market in Frankfurt, Munich |
|
EQS News ID: |
1168858 |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216006282/en/
Contact information
For media inquiries:
Oliver R. Baumann, CEO Xlife Sciences AG, Tel.+41 44 385 84 60
oliver.baumann@xlifesciences.ch
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lattice to Showcase Industry-Leading FPGA Innovations at FPGA Conference Europe 202616.6.2026 23:00:00 EEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its exhibition plan for the upcoming FPGA Conference Europe. Lattice will participate in various speaker sessions to showcase how low power FPGAs are driving innovation across multiple sectors. The company will also demonstrate its latest FPGA technology advancements in physical AI, advanced connectivity, security, and more. Who: Lattice Semiconductor What / When (GMT+2): June 30 – July 2: Lattice Presentations & Demo Showcase Speaker sessions: Day 1 – 3 Speaker Sessions: Lattice FPGA deep dive sessions spanning physical AI, advanced connectivity, security, and design tools Date Time Session June 30 9:45 a.m. FPGA Verification and Testing by Arrow 11:15 a.m. Trusted Resilience Edge: Unified FPGA-TPM for Post-Quantum Cryptography RED & Cyber Resilience Act 12 p.m. SIPHashIP for Embedded Security: Enabling RED Compliance and CRA Readiness in Smart AR/VR Systems 2:15 p.m. Foundations of FPGA Security
IQM Deploys Its First U.S. Quantum Computer at Oak Ridge National Laboratory16.6.2026 21:53:00 EEST | Press release
The Department of Energy's Oak Ridge National Laboratory (ORNL) today launched Pathfinder, the first commercially procured quantum computer at ORNL, built and deployed by IQM Quantum Computers. The 20-qubit IQM Radiance system marks IQM's first quantum computer installation in the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616373175/en/ IQM's first U.S. quantum computer is live — at DoE Oak Ridge National Laboratory. The deployment comes ahead of IQM's planned listing on the Nasdaq Global Select Market through its business combination with Real Asset Acquisition Corp. (Nasdaq: RAAQ), expected to close in mid-2026. ORNL is home to Frontier, the world's most powerful supercomputer for open science, and to one of the most consequential high-performance computing environments anywhere. Pathfinder now sits inside that environment, connected to HPC systems in the National Center for Computational Sciences Tec
Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology16.6.2026 20:00:00 EEST | Press release
Hologic, Inc. today announced a significant and far-reaching victory in the Unified Patent Court (UPC) in Germany, which ruled that Siemens* infringed upon a critical Hologic mammography technology patent in Siemens’ latest mammography system. The court imposed a sweeping injunction, immediately prohibiting Siemens from making, offering, placing on the market, using or importing or storing for those purposes its MAMMOMAT B.brilliant systems across Germany, France and the Netherlands, as well as monetary damages and penalties for non-compliance. The court also required Siemens to execute a mandatory recall and destruction of all affected systems in those countries. On June 10, 2026, the UPC determined that Siemens infringed upon European Patent EP 2 352 431, Hologic’s Focusing Technology on the Envision™ Platform, the first FDA-approved mammography innovation of its kind.1 In addition to the broad injunction against Siemens, recall and destruction of infringing systems, Hologic will rec
RealTime Reservation Acquires STAY to Create Leading Global Guest Experience Platform Serving 2,000+ Properties Across 75+ Countries16.6.2026 19:30:00 EEST | Press release
RealTime Reservation (RTR), the industry leader in dynamic hospitality booking technology for onsite activities, amenities, and ancillary revenue management, today announced its acquisition of STAY, creating a global end-to-end guest experience platform for the hospitality industry. The combined company will serve more than 2,000 hospitality properties across 75+ countries throughout North America, Europe, Latin America and the Caribbean. The combination significantly expands RTR's international footprint and strengthens its position as a leading provider of guest engagement, ancillary revenue, and guest experience technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616258776/en/ Pictured: RealTime Reservation's dynamic booking interface allows hotel guests to select and reserve pool and beach amenities by location, date, and availability, streamlining ancillary revenue management for properties of any size. Courte
Happy Holidays S.A. and JTA Investment Holding Announce €65 Million Investment for SARTIMARE Tourism Development in Greece16.6.2026 18:42:00 EEST | Press release
Happy Holidays S.A. today announced the signing of an Investment Agreement with Qatar-based JTA Investment Holding for the development of the sustainable SARTIMARE Beach Resort & Spa project in Sarti, Halkidiki, Greece. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616892834/en/ Dr. Amir Ali Salemi Zadeh, CEO of JTA Investment Holding and Georgios Iosifidis, Founder & Owner of Happy Holidays S.A. Under the agreement, JTA Investment Holding will invest €65 million into the development. The project will be built on a site of approximately 120,900 square meters, with construction scheduled between 2027 and 2030. Designed with a strong commitment to environmental responsibility, the SARTIMARE project will feature luxury hospitality facilities, premium residences and villas, wellness amenities, retail, food & beverage outlets, and marina infrastructure. The project's valuation is expected to exceed €100 million as key develop
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom